AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL

In our latest white paper, “AI-driven single-cell data analysis identifies a cell signature predictive of neurotoxicity and clinical response in CAR-T cell therapy of DLBCL”, we delve deep into the transformative impact of ScaiVision, Scailyte’s pioneering platform, on the realm of CAR-T cell therapy for Diffuse Large B-Cell Lymphoma (DLBCL).

Leveraging the power of single-cell omics alongside advanced AI, we’ve uncovered pivotal cellular signatures predictive of severe neurotoxicity and therapy response from a small dataset of 24 patient samples. Predicting treatment outcomes and identifying potential neurotoxicity risks has tremendous potential to ensure a safer, more tailored therapeutic journey for each patient treated by CAR-T therapies.

We invite you to explore the contribution of single-cell technologies and our AI-driven data analysis approach to advance CAR-T therapy.

Join us in this exciting journey towards a future where cancer treatment is not only effective but also uniquely personalized.